Hence, FGF21 could be considered a potential diagnostic biomarker and therapeutic agent for metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and fatty liver (4). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.